NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

NovaBridge BiosciencesNASDAQ: NBP

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income growth accelerates

Q4 FY2025 net income of $72.86M (cash outflow) rose 10.2% year over year, ahead of the -47.8% change in trailing-twelve-month net income. Sequentially, it rose 49.7% from the prior quarter. Over 3 fiscal years it compounded at -67.2% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$138.98M (+57.3%) for the fiscal year ending Dec 2026, a step up from the -75.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$72.86M+49.7% QoQ
Last fiscal yearDec 2025
-$88.34M-75.6% YoY
LTMSep 2025
-$150.96M-47.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.2%+66.1%+55.9 pp
1 year-75.6%+57.3%+133.0 pp
3-year CAGR-67.2%+36.3%+103.5 pp
5-year CAGR+20.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
(88.34M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.8% is the lowest of 10, against a peer median of +18.7%.
  • Over three fiscal years its annual growth of -67.2% compares with a peer median of +10.7%.
NBP Competitors
Net Income for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M USD-18.9%+0.2%—
ANNXAnnexon, Inc.LTM Mar 2026$196.48M USD+17.4%+13.3%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥150.96M CNY-47.8%-67.2%—
ENGNenGene Holdings Inc.LTM Apr 2026$126.85M USD+58.8%+68.6%—
AURAAura Biosciences, Inc.LTM Mar 2026$112.39M USD+18.7%+21.8%—
ALTAltimmune, Inc.LTM Mar 2026$91.08M USD+0.9%+1.3%253002.8%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$69.71M USD+24.0%+3.3%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$42.63M USD+34.3%+8.1%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M USD—+20.7%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$35.1M USD+30.0%+33.8%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$26.25M USD-41.9%-7.4%—
Peer median (excluding NBP) —+18.7%+10.7%253002.8%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Net Income(2.33B)(2.51B)(208.18M)(362.72M)(88.34M)
Depreciation & Amortization34.14M63.82M1.06M7.14M856K
Deferred Income Tax00000
Stock-Based Compensation608.61M357.15M10.26M(14.23M)5.97M
Change in Working Capital394.52M552.06M(37.2M)(20.52M)17.07M
Accounts Receivables97.42M33.08M000
Inventory(27.24M)27.24M000
Accounts Payables107.85M0000
Other Working Capital216.49M491.75M(37.2M)(20.52M)17.07M
Other Non-Cash Items321.18M431.48M161.2M5.9M43.84M
Operating Cash Flow(973.09M)(1.1B)(72.85M)(384.42M)(20.6M)
Capital Expenditures(29.93M)(45.83M)(164.35K)(350.34K)(7K)
Acquisitions (Net)(6M)0000
Purchases of Investments(10.17B)(7.41B)0(1.79B)(49.96M)
Sales of Investments9.48B7.91B0801.66M154.89M
Other Investing Activities026K(107.47M)452.53K47K
Investing Cash Flow(727.21M)458.38M(107.63M)(992.42M)104.97M
Debt Repayment02.75M000
Common Stock Issued000061.91M
Common Stock Repurchased0(3.08M)(8.66M)(2.45M)0
Dividends Paid00000
Other Financing Activities593.92M60.86M407.88K0(4.19M)
Financing Cash Flow593.92M42.36M(8.25M)(2.44M)57.73M
Effect of Forex Changes(128.77M)389.2M36.89M(327.04M)276K
Net Change in Cash(1.24B)(212.86M)(151.58M)(1.71B)142.37M
Free Cash Flow(1B)(1.15B)(73.02M)(384.77M)(20.6M)

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.